To investigate the role of PIK3CA oncogene in tumorigenesis and development of esophageal cancer in Chinese patients at the levels of genetic mutation and epigenetics. Seventy six esophageal tumor ...
Aspirin reduced colorectal cancer recurrence risk by 50% in patients with PIK3CA mutations over three years. Mutations in the PI3K pathway predict aspirin response, broadening its use to more patients ...
Alpelisib (ALP) with fulvestrant (FUL) in patients (pts) with PIK3CA-mutated hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC): ...
Mutations in the PIK3CA gene are a key driver of breast cancer and are present in 35–40% of hormone receptor–positive breast cancers. A recently completed phase 3 clinical trial, conducted by ...
Additional analysis of data from a Phase 1b clinical trial that included all patients treated with gedatolisib combined with fulvestrant and palbociclib showed median progression-free survival (“PFS”) ...
CHICAGO -- Adding the PI3K-pathway inhibitor inavolisib (Itovebi) to palbociclib (Ibrance) and fulvestrant significantly improved survival in advanced breast cancer patients with PIK3CA-mutated, ...
Factors associated to treatment delay in women with primary breast cancer who were referred to reproductive specialists. This is an ASCO Meeting Abstract from the 2018 ASCO Annual Meeting I. This ...
The US Food and Drug Administration (FDA) has approved inavolisib (Itovebi, Genentech) in combination with palbociclib and fulvestrant for endocrine-resistant, PIK3CA-mutated, hormone ...
The outlook for someone with PIK3CA-related overgrowth spectrum (PROS) depends on factors that vary from person to person. Early intervention and treatment can improve the outlook and prevent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback